Table 2.
Adverse events according to immunotherapy.
| Event (number, %) | Any Grade | Grade 3/4 |
|---|---|---|
| Treatment-related adverse events | 31 (72.1) | 19 (44.2) |
| Hypopituitarism | 9 (20.9) | 5 (11.6) |
| Maculopapular rash | 7 (16.3) | 0 |
| Increased AST | 5 (11.6) | 5 (11.6) |
| Increased ALT | 5 (11.6) | 5 (11.6) |
| Colitis | 4 (9.3) | 3 (7.0) |
| Hypothyroidism | 4 (9.3) | 1 (2.3) |
| Pneumonitis | 4 (9.3) | 0 |
| Pruritus | 4 (9.3) | 0 |
| Arthritis | 3 (7.0) | 2 (3.5) |
| Myalgia | 3 (7.0) | 2 (3.5) |
| Weight loss | 2 (3.5) | 1 (2.3) |
| Hyperglycemia | 1 (2.3) | 1 (2.3) |
| Rheumatoid arthritis | 1 (2.3) | 1 (2.3) |
| Hyperthyroidism | 1 (2.3) | 0 |
| Increased creatinine | 1 (2.3) | 0 |
| Urticaria | 1 (2.3) | 0 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase.